Abstract: The present invention has disclosed SHP2 phosphatase inhibitors and its applications. Specifically, the present invention has disclosed the compounds shown in the general formula (I), methods of preparation thereof, and pharmaceutical compositions containing the compound, and their use as tyrosine phosphatase SHP-2 inhibitors in the treatment of leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, pancreatic cancer, head and neck squamous cell carcinoma, stomach cancer, liver cancer, anaplastic large cell lymphoma, and glioblastoma, wherein each substituent in general formula (I)k is as defined in the specification.

Abstract: Disclosed are a heterocyclic compound acting as a BTK (Bruton's Tyrosine Kinase) inhibitor, a preparation method and a medical application thereof. Specifically, the present disclosure relates to a compound represented by the general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and/or the pharmaceutically acceptable salt thereof, and a use applying the compound or the pharmaceutically acceptable salt in the treatment or prevention of BTK-related disorders, especially tumors. The present disclosure relates to a class of heterocyclic compounds and at the same time provides the preparation method for the pharmaceutical composition containing this class of compounds or the pharmaceutically acceptable salt thereof. Each substituent of the general formula (I) has the same definition as that in the specification.

Abstract: Disclosed are a heterocyclic compound used as a FGFR (Fibroblast Growth Factor Receptor) inhibitor, a preparation method thereof, and a pharmaceutical application thereof. Specifically, the present disclosure relates to a compound represented by general formula I and a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the found and/or the pharmaceutically acceptable salt, and a use of the compound or the pharmaceutically acceptable salt in treating or preventing disorders related to FGFR kinase, specifically tumor drugs, and the compound is a class of heterocyclic compound, and at the same time the present disclosure provides a preparation method for the pharmaceutical composition of the compound and the pharmaceutically acceptable salt. Definition of substituents in general formula I is identified with that in the description.

Abstract: A controller for a power converter formed with a plurality of converter stages, and method of operating the same. In one embodiment, the controller includes a power system controller configured to determine an unequal current allocation among the plurality of converter stages based on an operation of the power converter. The controller also includes a converter stage controller configured to control an output current produced by each of the plurality of converter stages in response to the current allocation.

Abstract: Provided is a composition of detection agents for living cells, especially epithelial tumor cells; the composition contains 0-5% folic acid, 0-10% folic acid complex, 0.01-5% methylene blue, 0.1-10% carbohydrate reducing agent, 2-6% acetic acid, and 3-95% water. Also provided is a preparation method for the composition of detection agents and kits containing the composition of detection agents.

Abstract: A controller for a power converter formed with a plurality of converter stages, and method of operating the same. In one embodiment, the controller includes a power system controller configured to determine an unequal current allocation among the plurality of converter stages based on an operation of the power converter. The controller also includes a converter stage controller configured to control an output current produced by each of the plurality of converter stages in response to the current allocation.

Abstract: A controller for a power converter formed with a plurality of converter stages, and method of operating the same. In one embodiment, the controller includes a power system controller configured to determine an unequal current allocation among the plurality of converter stages based on an operation of the power converter. The controller also includes a converter stage controller configured to control an output current produced by each of the plurality of converter stages in response to the current allocation.

Abstract: A controller for a power converter formed with a plurality of converter stages, and method of operating the same. In one embodiment, the controller includes a power system controller configured to determine an unequal current allocation among the plurality of converter stages based on an operation of the power converter. The controller also includes a converter stage controller configured to control an output current produced by each of the plurality of converter stages in response to the current allocation.

Abstract: Provided is a composition of detection agents for living cells, especially epithelial tumor cells; the composition contains 0-5% folic acid, 0-10% folic acid complex, 0.01-5% methylene blue, 0.1-10% carbohydrate reducing agent, 2-6% acetic acid, and 3-95% water. Also provided is a preparation method for the composition of detection agents and kits containing the composition of detection agents.